A similar level of ERK hyperactivation in both melanoma subtypes was observed also in response to a structurally unrelated small-molecule inhibitor 4E1RCat, which blocks the eIF4F complex activity by disrupting the interaction of the eIF4G and eIF4E subunits (Fig. 2B). This evidence concerns the gene MAPK1 and melanoma.